Navigation Links
Telik Announces Third Quarter 2012 Financial Results
Date:11/9/2012

PALO ALTO, Calif., Nov. 9, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $1.9 million, or $0.78 per share, for the third quarter ended September 30, 2012, compared with a net loss of $2.8 million, or $1.58 per share (adjusted for the 1-for-30 reverse split of the company's common stock effected on March 30, 2012), for the comparable period in 2011.

For the quarter ended September 30, 2012, total operating costs and expenses were $1.9 million, compared with $2.9 million in the third quarter of 2011. Operating expenses in the 2012 third quarter included stock-based compensation expense of approximately $0.1 million. Operating expenses were approximately 34% lower in the third quarter of 2012 compared with the same period in 2011, primarily due to lower headcount, corporate and stock-based compensation expenses.

For the nine months ended September 30, 2012, Telik reported a net loss of $6.2 million, or $3.07 per share, compared with a net loss of $9.5 million, or $5.30 per share, for the same period in 2011.  Total operating expenses for the first nine months of 2012 were $6.2 million, compared with $9.6 million for the same period in 2011. Operating expenses in the first nine months of 2012 included approximately $0.6 million in stock-based compensation expense. The reduction in operating expenses of approximately 35% in the first nine months of 2012 compared with the same period in 2011 was primarily due to lower headcount, reduced clinical trial expenses, and lower corporate and stock-based compensation expenses.

At September 30, 2012, Telik had $6.6 million in cash, cash equivalents and investments including restricted investments, compared to $11.7 million at December 31, 2011. In order to meet its current cash requirements beyond the first quarter of 2013, the company will have to raise additional funds through corporate partnering or equity financings. Although the company has been able to raise funds through its At Market Issuance Sales Agreement, there is no assurance Telik will be successful in obtaining additional funding in the near future.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.Telik, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Nine Months EndedSeptember 30,September 30,2012201120122011Operating costs and expenses:Research and development 

$
867$
,305$
2,788$
4,464General and administrative 

1,0111,5503,4235,090Total operating costs and expenses

1,8782,8556,2119,554Loss from operations

(1,878)(2,855)(6,211)(9,554)Interest and other income (expense), net

27631Net loss

$
(1,876)$
(2,848)$
(6,205)$
(9,523)Basic and diluted net loss per share*

$
(0.78)$
(1.58)$
(3.07)$
(5.30)Weighted average shares used to calculate basic and diluted net loss per share*

2,3951,7992,0211,796* Adjusted for the 1-for-30 reverse stock splitSelected Balance Sheet Data(In thousands)(Unaudited)September 30,December 31,20122011Cash, cash equivalents, investments and restricted investments

$
,642$
,700Total assets

7,44512,412Stockholders' equity

4,6278,299
'/>"/>

SOURCE Telik, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
2. Cannabis Science Provides Corporate Guidance on Preclinical Initiatives and Recent Corporate Developments for its Shareholders; CBIS Announces plans for 1st Q of 2013 Webinar Investor Call
3. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
4. IntelliCell BioSciences Announces FDA Registration for its Cell Processing Facility
5. NxStage Announces Fourth Quarter 2012 Investor Conference Schedule
6. Unilife Corporation Announces Financial Results For Fiscal Year 2013 First Quarter
7. Array BioPharma Announces Proposed Public Offering Of Common Stock
8. Allscripts Announces Third Quarter 2012 Results
9. Jazz Pharmaceuticals Announces Third Quarter 2012 Results
10. Protalex, Inc. Announces Screening Of First Patients In U.S. For New Trial Of PRTX-100 In Patients With Active Rheumatoid Arthritis
11. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
(Date:4/19/2017)... India , April 19, 2017 ... and Application, Forecast to 2022 report has covered and analysed ... statistics and information on market size, shares and growth factors. ... major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, ...
Breaking Medicine Technology:
(Date:4/22/2017)... ... April 22, 2017 , ... ... Security of Philadelphia its “Woman-Owned Small Business of the Year, eastern ... information destruction , recycling, and compliance services to businesses throughout eastern ...
(Date:4/21/2017)... ... ... Providing broad access to life-saving drugs and rewarding the innovators who develop those ... this problem. , That was the message from Dana Goldman, PhD, Leonard D. Schaeffer ... Southern California, who served as the keynote speaker for Western University of Health Sciences’ ...
(Date:4/21/2017)... ... ... Brady (NYSE:BRC), a global leader in industrial and safety printing systems ... label materials received certification for the BS5609 British Marine Standard. This internationally recognized standard ... use on chemical drums shipped by sea. , “Achieving BS5609 certification for ...
(Date:4/21/2017)... ... April 21, 2017 , ... The VIA Agency ... (AOR) for Theravent, Inc. , the makers of a revolutionary new device ... Healthcare, is now working to expand distribution in anticipation of a national launch. ...
(Date:4/21/2017)... ... 2017 , ... Airway Management, the medical device manufacturer of ... and well renowned Asian distributor, Discovery Sleep. The agreement involves the ... and will stabilize and strengthen Airway’s presence with a dedicated, reputable medical device ...
Breaking Medicine News(10 mins):